Health Insurance Marketplace Plans and People Living With HIV and/or Viral Hepatitis: The Success of the Affordable Care Act Requires Fair Drug Pricing and Access
The Affordable Care Act (ACA) has the potential to vastly improve health care coverage in the United States. This is a welcome development for the Fair Pricing Coalition (FPC), which has consistently advocated for improved access to affordable medications for the estimated 1.2 million people living with HIV/AIDS and the more than 3.2 million people living with chronic hepatitis C virus (HCV) infection in this country.
As people begin accessing care via Qualified Health Plans (QHPs) in the health insurance marketplaces, or exchanges, the FPC has identified issues and challenges that must be addressed, through sound government policies and cooperation of the pharmaceutical and health insurance industries, to ensure affordable access to essential medicines. These issues and challenges include:
- Some health insurance companies are engaging in discriminatory practices. A clear mandate of ACA is to prevent companies from denying coverage to people with pre-existing and/or chronic health conditions. FPC and others have documented that some QHPs are not including certain standard-of-care HIV medications, including single-tablet regimens, in their formularies, and many are placing HIV and HCV drugs in tiers associated with exorbitant out-of-pocket (OOP) costs (see next paragraph). In effect, insurance companies participating in federal and state marketplaces are placing the burden of paying for life-saving drugs on people who have chronic conditions, essentially circumventing the non-discrimination backbone of ACA.
- High out-of-pocket (OOP) expenditures. Many marketplace QHPs are placing prescription medications for HIV and HCV in high "specialty drug" tiers (Tier 4 or 5), which impose exorbitant OOP costs in the form of co-insurance (i.e., patients pay a percentage of prescription drug costs, rather than a flat co-payment). According to a survey of 600 QHPs conducted by Avalere Health, a data analysis firm, roughly 91 percent had specialty drug tiers, compared with only 23 percent of employer-based plans.
Under some QHPs -- depending on the state, level of the plan (bronze, silver, gold, or platinum), and a drug's tier placement -- people are paying as much as 40 to 50 percent of their prescription costs. Though ACA requires QHPs to cap their OOP costs -- individuals may be required to pay up to $6,350 in annual copayments, co-insurance, or deductibles ($2,250 if their incomes are less than 200 percent of the federal poverty level (FPL), or $5,200 for those with incomes between 200 and 250 percent of FPL)1 -- many people with HIV and/or HCV would incur the maximum OOP for their medications, likely in the first few months of each annual cycle.
- High drug prices. In addition to discriminatory health insurance industry practices, high wholesale prices of drugs used to treat HIV and HCV are a key driver of QHPs placing standard-of-care medications on the highest co-payment and co-insurance tiers, resulting in prohibitive OOP costs. Not only do newly approved drugs for these diseases typically enter the market at price points higher than their immediate predecessors -- often despite comparable efficacy, safety, and dosing -- but also, annual and semi-annual drug price increases far exceed, and contribute to, growth in inflation.
For example, the single-tablet regimen Atripla (efavirenz/emtricitabine/tenofovir DF) is among the least expensive U.S. Department of Health and Human Services (HHS)-preferred drug combinations for HIV. The current estimated wholesale acquisition cost (WAC), the publicly available price for medications, is $24,026 per year. This reflects a 6.6% increase over the 2013 WAC price and a 12.3% increase over the 2012 WAC price. For comparison, the Consumer Price Index (CPI), a measure of U.S. inflation, rose only 1.4% in 2013. The medical CPI for 2013 was 2.5%.
Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir DF), Gilead Sciences' single-tablet regimen approved by the U.S. Food and Drug Administration (FDA) in August 2012, entered the market with an annual WAC price of $28,500. The WAC price increased 4.9% in January 2014.
Tivicay (dolutegravir), ViiV Healthcare's once-daily integrase inhibitor, approved in August 2013, entered the market with an annual WAC price of $14,105 ($28,210 for those requiring twice-daily dosing, which includes people living with HIV resistant to other integrase inhibitors and those taking certain non-HIV medications). The WAC price increased 4.9% in January 2014. Additionally, Tivicay must be combined with other HIV medications, usually Truvada (emtricitabine/tenofovir DF) or Epzicom (abacavir/lamivudine), with annual WAC prices of approximately $15,000 and $14,000, respectively.
Gilead Sciences' Sovaldi (sofosbuvir), approved in December 2013 for the treatment of HCV, has gained notoriety for its pricing debut: $84,000 for twelve weeks of treatment. Combined with other drugs required to treat HCV, notably pegylated interferon and/or ribavirin, a single course of therapy containing Sovaldi is associated with a WAC price between $93,000 and $168,000.
For people living with HIV and/or HCV, there are no generic equivalents to standard-of-care drugs.
- Lack of transparency regarding drug formularies and the associated cost sharing. People living with HIV and/or HCV must have access to comprehensive information detailing QHP formularies and their associated OOP expenses in order to make an educated plan choice. Currently, it is extremely difficult to access the correct plan formulary and virtually impossible to fully understand the cost-sharing obligations associated with individual drugs. The federally facilitated marketplace does have a link to plan formularies, but the information is not always correct. Some state marketplaces, including Covered California, don't provide links to plan formularies.
- Soaring drug prices limit access and are bad business practices. Because a large percentage of Medicaid, private insurance, and Ryan White expenditures are directly related to prescription drug costs, compounded by growing political intolerance for disease-specific funding and nationwide efforts to reduce health care spending in the U.S., prescription drug cost containment is not so much a desire as it is a necessity.
Restricted budgets among public programs (which cover a substantial number of people living with HIV and/or HCV), as well as strategies intended to control costs among QHPs, would indicate that new drugs should match or undercut existing products on price to earn their place as better treatments. Even if a new product's efficacy, safety, and dosing convenience are incrementally better than those of currently used HIV or HCV medications, the price will increasingly determine formulary inclusion and accessibility. Higher pricing in an increasingly competitive market will ultimately translate into a missed opportunity to recoup development costs, and potentially better drugs will be underutilized.
Mechanisms also need to be put in place to ensure that savings -- as a result of voluntary wholesale price containment by manufacturers, pricing approaches available to payers (e.g. use of purchasing pools, higher rebates through market leverage, use of restricted pharmacy networks), or regulatory efforts (e.g., expanded access to Medicaid rebates, direct price regulation, or regulation of direct-to-consumer advertising practices) -- are reinvested in programs, such as supportive/ancillary care services needed for prevention, improvement of universal HIV and HCV testing, implementation of engagement-in-care best practices, and maximization of treatment utilization (i.e., only 25% of people living with HIV have maximally suppressed virus as a result of antiretroviral therapy use). Ensuring that HIV and HCV treatment cost savings are reabsorbed by other HIV and viral hepatitis programs is critical, considering that the objectives of the 2010 National HIV/AIDS Strategy and the 2011 Viral Hepatitis Action Plan, absent new funds, are to be financed by redirected fiscal resources.
- Co-payment assistance programs are in a state of flux. Some manufacturers have indicated that they are unwilling to extend their co-payment assistance programs to QHP beneficiaries because of conflicting government guidance.
In an October 2013 letter to Representative Jim McDermott (D-WA), U.S. Health and Human Services (HHS) Secretary Kathleen Sebelius indicated that the agency would permit drug manufacturers to defray patient co-payments, stressing that QHPs offered through ACA's health insurance marketplaces do not constitute federal health care programs and, as a result, are not affected by the federal anti-kickback statute (42 USC § 1320a-7b). The HHS Center for Consumer Information and Insurance Oversight (CCIIO), however, then issued a contradictory statement in a Q&A document: "HHS discourages this practice and encourages issuers to reject such third party payments." Legislative mandates to explicitly ban co-payments under ACA are being sought by Senators Chuck Grassley (R-IA) and David Vitter (R-LA).
This provision is already a barrier for people living with HIV and/or HCV who receive treatment under Medicare Part D and face unaffordable OOP costs, particularly in the case of most HIV and HCV medications that do not have suitable generic equivalents.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy